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explore the cost implications of prescribing Ellipta portfolio in appropriate patients 
versus alternative therapies, in line with clinical guidelines. Methods: a one-year 
BIM was constructed to explore financial implications of prescribing Ellipta medi-
cines as alternative treatment options to currently prescribed therapies. The BIM is 
based on UK prescription analysis, epidemiological and resource data. The BIM uses 
prescription data to generate patient cohorts and progresses them to more intensive 
therapy based on estimates of symptoms of exacerbation or breathlessness. It also 
considers medicines optimsation for patients that could benefit from simplified regi-
mens and estimates the budget impact of moving patients using non-licensed ICS/
LABA to licensed therapies. The model allows definition of treatment progressions, 
using appropriate Ellipta devices to target bronchodilator or steroid based regimens. 
Costs are calculated using market share of current treatments vs. a scenario in which 
Ellipta medicines are used. Differences in patient outcomes, efficacy or safety are not 
explored. Results: It is estimated that the average health economy in the UK has 
5,518 COPD patients of whom 1,320 are eligible to be progressed in their medication. 
In year 1, compared to a base case of utilising the most routinely used existing COPD 
therapies (100% implementation rate for new incident patients and 50% for all oth-
ers) would increase spend by £247,830 compared with a reduced budget impact of 
-£131,920 if these eligible patients were moved to Ellipta medicines. ConClusions: 
The introduction of Ellipta portfolio in COPD could potentially reduce the budget 
impact and total spend on COPD therapies by £379,750 in the average UK health 
economy compared to current prescribing patterns. Funded by GSK
PRS21
Budget ImPact analySIS Of fORmOteROl eaSyhaleR In the tReatment 
Of aSthma In chIldRen In the RuSSIan fedeRatIOn
Kulikov A, Kilimanova E
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To conduct the budget impact analysis of Formoterol Easyhaler, which 
allowed to determine the net economic effect of the budget impact in regards of 
replacement of one medicine to another. Methods: Information search was con-
ducted in the public domain. Pharmacoeconomic analysis method – budget impact 
and direct cost analysis were performed. Results: In this study, given the phar-
macoeconomic evaluation of drugs Formoterol Easyhaler, Oxis Turbuhaler, Foradil 
Aerolizer and Atimos. The study had a time horizon of one year. The daily dose of 
formoterol was 24 mcg. Cost analysis was conducted on the cost of basic phar-
macotherapy, compensation costs for treatment of exacerbations, compensation 
costs for side effects and adverse reactions. The total direct cost per patient with 
asthma amounted to 1 262, 17$ to the Easyhaler group, 1 581, 83$ to the Turbuhaler 
group, 1 498,95 and 1 499,99 to the Foradil (30 and 60 doses), and 1 705, 06$ to the 
Atimos. The selection of budget impact method of pharmacoeconomic analysis 
was determined by the advantages of Formoterol Easyhaler in terms of its effi-
ciency and lower value of total direct costs. In the present study, based on the 
results of the “cost analysis” it was revealed that the replacement formoterol of Oxis 
Turbuhaler, Foradil Aerolizer (30 and 60 doses) and Atimos on Easyhaler saved per 
patient respectively 319,66$, 236,78$ (187, 82$ for 60 doses) and 442,89$ for the health 
care system budget. ConClusions: The budget impact analysis results obtained 
in this Formoterol Easyhaler versus others drugs of formoterol comparative study 
demonstrated that Easyhaler therapy resulted in budget saving.
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objeCtives: Allergic rhinitis (AR) is a chronic disease of the upper respiratory tract 
caused by exposure to allergens inducing inflammation of the nasal mucosa and of 
the conjunctiva mediated by antibody Immunoglobulin E (IgE). According to local 
literature, prevalence of symptomatic AR is around 20% and grass pollen is the most 
common allergen causing A (%5 of uncontrolled moderate / severe AR) in Turkey. 
Allergen-specific immunotherapy (AIT) is recommended as a second line treatment 
for patients with moderate to severe allergic rhinitis not or poorly controlled by 
symptomatic treatments.The Five Grass Pollen Sublingual Tablet (5GPST) is an alter-
native AITin Turkey. The aim of this budget impact model (BIM) was to assess the 
cost saving potential of the 5GPST inthe Turkish reimbursement system. Methods: 
Cost calculations were madefrom the payer perspective as per the guidelines of the 
Social Security Institution (SSI). The time horizon considered in the model was one 
year. The clinical data and Rescue Medication Scores were acquired from published 
clinical studies. Direct medical costs were considered in this analysis. Pricing and 
reimbursement prices data are obtained from Ministry of Health Drug Price List and 
the Price List of SSI Health Implementation Guideline. Results: According to the 
BIM, total cost of AR treatment for a patient treated with symptomatic treatment 
alone was 373 TL per year and reached 1.607 TL per year for patients receiving sub-
cutaneous immunotherapy. Total cost of AR with5GPSTwith %11discount for the first 
reimbursement year was 1.168 TL. Total yearly cost of AR with 5GPST with % 41 dis-
count was 864 TL. ConClusions:: Compared to subcutaneous AIT, 5GPST is a cost 
saving alternative fortreatment of seasonal AR in Turkey from a SSI perspective. The 
treatment is 27% or 46% cheaper applying 11% or 41% discount rates respectively.
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mixed-treatment comparison) were applied at 2 weeks. Lung function decline after 
2 weeks was applied independent of treatment arm but dependant on GOLD stage. 
Exacerbation risk, health outcomes and costs of COPD management were calculated 
based on GOLD stage. Cost inputs were taken from published literature. Results: 
The 5-year budget impact of displacement of tiotropium by tiotropium + olodaterol 
Respimat®was a cost-saving of £25.8 million, £2.7 million, £1.6 million, and £0.9 
million, in England, Scotland, Wales, and Northern Ireland respectively. These 
cost-savings were largely driven by a predicted 0.8% reduction in COPD manage-
ment costs, and a predicted 0.9% reduction in the costs of exacerbation manage-
ment. ConClusions: Switching patients with COPD from tiotropium maintenance 
to tiotropium + olodaterol Respimat® maintenance therapy has the potential to 
be cost-saving to the UK NHS. These cost-savings largely result from a predicted 
reduction in primary and secondary care costs. Whilst treatment switching should 
be driven by clinical rationale and patient preference, this finding has implications 
for medicine optimisation in the UK.
PRS18
the Budget ImPact Of an InhaleR WIth ImPROved featuReS cOmPaRed 
tO SPIRIva® handIhaleR® fOR the management Of chROnIc 
OBStRuctIve PulmOnaRy dISeaSe (cOPd) In the uk: eStImated ImPact 
On unScheduled healthcaRe cOStS and InhaleR SatISfactIOn
Nicolai J1, Torvinen S1, Howard DJ2, Miles R2, Greaney MH2, Comberiati U1, Plich A1
1Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands, 2Adelphi Values Ltd, Bollington, 
UK
objeCtives: Spiriva® Handihaler® (tiotropium) is a single capsule dry powder 
inhaler (DPI) for the treatment of COPD. A budget impact model was developed 
to assess the potential economic impact of introducing an inhaler with improved 
features compared to Spiriva® Handihaler®to treat COPD in the UK. The potential 
cost benefit of increasing treatment satisfaction, due to the improved characteris-
tics of this new inhaler was investigated. Methods: The eligible patient popula-
tion presented was based on the number of confirmed COPD diagnoses in the UK, 
with the proportion of patients receiving Spiriva® Handihaler® based on market 
research data. The costs of scheduled and unscheduled healthcare events presented 
within the model were taken from publically available UK sources. Findings from a 
multinational, cross-sectional, real-world survey of 1,443 COPD patients associat-
ing inhaler attributes, inhaler satisfaction, adherence and patient health status 
were used within the model to determine the correlations between inhaler sat-
isfaction, treatment adherence and unscheduled healthcare events. Using these 
correlations, an annual number of UK unscheduled healthcare events associated 
with COPD was calculated for patients using a new improved inhaler and Spiriva® 
HandiHaler®. Results: The annual UK costs of treating COPD patients for unsched-
uled healthcare events were € 1027.05 with Spiriva® HandiHaler®vs. € 922.14 with 
the new inhaler. Potential budgetary savings achieved by using the new inhaler 
instead of HandiHaler® were calculated at € 104.91 per patient and € 16.69 million 
for the UK COPD patient population per year. ConClusions: There is a potential 
for a new improved tiotropium inhaler to offer budgetary savings compared with 
Spiriva® Handihaler® resulting from cost benefits due to increased patient satis-
faction with their inhaler.
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objeCtives: This study estimated the total expenditure on prescribed Seasonal 
Allergic Conjunctivitis (SAC) medication in the UK and the budget impact of switch-
ing patients to alternative treatments. Methods: A budget impact model devel-
oped from the UK NHS and Personal Social Services (PSS) perspective was used 
to evaluate total spending on: olopatadine, generic sodium cromoglicate, branded 
sodium cromoglicate, nedocromil sodium. A 4-month time horizon was applied 
(average allergy season duration). Direct to patient data (National Health and 
Wellness Survey [NHWS]) were used to estimate the number of patients receiving 
prescription SAC treatment. Published 42-day efficacy data were input for each 
product, with patients classified as either successfully treated or unsuccessfully 
treated at 14, 28, 42, and 120 days. Unsuccessful treatment required additional 
resource use and switch to further therapy. Two approaches extrapolated clinical 
data to 120 days: A) No decline after 42-days, B) linear decline in efficacy. Cost per 
treatment was estimated and multiplied by its market size to estimate the total 
current spend in the UK. Model structure and inputs were validated with clinical 
KOLs. Results: Under scenario A olopatadine treatment was associated with the 
lowest cost. Olopatadine spending over a four month period was £100.08 versus 
£104.39 for sodium cromoglicate. Under scenario B, sodium cromoglicate treatment 
resulted in costs of £114.97 versus £124.07 with olopatadine. An estimated 3,161,807 
UK adults are treated in the Rx market (NHWS). Total spending was estimated to 
exceed £300,000,000 under all scenarios. Under scenario A switching all patients 
to olopatadine may result in savings of £15,378,769. ConClusions: Increasing 
olopatadine market share in SAC may be cost-saving when compared against alter-
native treatments for SAC. The use of direct to patient surveys are an important 
source in market sizing when considering markets split across prescription and 
over-the-counter treatments.
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objeCtives: The GSK Ellipta portfolio medicines are licensed for treatment of COPD 
in the UK and is comprised of fluticasone furoate/vilanterol, umeclidinium bromide/
vilanterol and umeclidinium bromide. A budget impact model (BIM) was designed to 
